STOK - Stoke Therapeutics, Inc.
IEX Last Trade
11.41
-0.020 -0.175%
Share volume: 7,377
Last Updated: Thu 26 Dec 2024 08:30:20 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$11.43
-0.02
-0.17%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-14 | 2023-03-06 | 2023-05-04 | 2023-08-07 | 2023-11-07 | 2024-03-25 | 2024-05-06 | |
| Total revenue | 3.231 M | 2.905 M | 3.269 M | 5.152 M | 0.000 | 3.308 M | 320.000 K | 4.216 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 3.231 M | 2.905 M | 3.269 M | 5.152 M | 0.000 | 3.308 M | 320.000 K | 4.216 M | |
| -10.09% | 12.53% | 57.60% | -100.00% | inf% | -90.33% | 1,217.50% | |||
| Operating expenses | 28.469 M | 30.053 M | 30.444 M | 29.842 M | 30.781 M | 30.542 M | 32.388 M | 32.588 M | |
| Selling general and admin | 10.111 M | 9.944 M | 9.383 M | 10.211 M | 10.230 M | 10.271 M | 10.610 M | 10.220 M | |
| Research and development | 18.358 M | 20.109 M | 21.061 M | 19.631 M | 20.551 M | 20.271 M | 21.778 M | 22.368 M | |
| Total expenses | 28.469 M | 30.053 M | 30.444 M | 29.842 M | 30.781 M | 30.542 M | 32.388 M | 32.588 M | |
| 5.56% | 1.30% | -1.98% | 3.15% | -0.78% | 6.04% | 0.62% | |||
| Operating income | -25.238 M | -27.148 M | -27.175 M | -24.690 M | -30.781 M | -27.234 M | -32.068 M | -28.372 M | |
| Ebit | -25.238 M | -27.148 M | -27.175 M | -24.690 M | -30.781 M | -27.234 M | -32.068 M | -28.372 M | |
| Pretax income | -24.652 M | -26.111 M | -25.655 M | -22.545 M | -30.654 M | -24.542 M | -26.958 M | -26.374 M | |
| 5.92% | -1.75% | -12.12% | 35.97% | -19.94% | 9.84% | -2.17% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -24.652 M | -26.111 M | -25.655 M | -22.545 M | -30.654 M | -24.542 M | -26.958 M | -26.374 M | |
| -5.92% | 1.75% | 12.12% | -35.97% | 19.94% | -9.84% | 2.17% | |||
| Net income | -24.652 M | -26.111 M | -25.655 M | -22.545 M | -30.654 M | -24.542 M | -26.958 M | -26.374 M | |
| -5.92% | 1.75% | 12.12% | -35.97% | 19.94% | -9.84% | 2.17% |